



Correction

Correction: Zheng et al. Glycolysis-Related SLC2A1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy. *Cancers* 2022, 14, 5344

Haosheng Zheng ^{1,†}, Guojie Long ^{2,3,†}, Yuzhen Zheng ¹, Xingping Yang ¹, Weijie Cai ¹, Shiyun He ¹, Xianyu Qin ^{1,*} and Hongying Liao ^{1,*}

- Department of Thoracic Surgery, Thoracic Cancer Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510655, China
- Guangdong Research Institute of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou 510655, China
- Department of Pancreatic Hepatobiliary Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou 510655, China
- * Correspondence: qinxy27@mail.sysu.edu.cn (X.Q.); liaohy2@mail.sysu.edu.cn (H.L.); Tel.: +86-139-2884-5885 (H.L.)
- † These authors contributed equally to this work.

The authors wish to make the following corrections to this paper [1]:

In the published version, there were mistakes in "3.9. Immune Cell Infiltration Analysis of SLC2A1" of page 14 and Figure 10.

On page 14, in the Section "3.9. Immune Cell Infiltration Analysis of SLC2A1".

The sentence "SLC2A1 expression is negatively correlated with CD8+ T cells in 12 types of cancers (STES, TGCT, ESCA, LUSC, SKCM, LUAD, BLCA, HNSC, CESC, LAMLC, THYM, and GBM), but positively with CD8+ T cells in 5 types of cancers (PRAD, KIPAN, KIRP, CHOL, and LIHC) (Figure 13A)." should be changed to "SLC2A1 expression is negatively correlated with CD8+ T cells in 9 types of cancers (LUSC, TGCT, HNSC, CESC, LUAD, LAML, SKCM, THYM, and GBM), but positively with CD8+ T cells in 4 types of cancers (PRAD, KIPAN, UVM, and CHOL) (Figure 13A)."

The sentence "SLC2A1 expression is negatively correlated with CD8+ T cells in 12 types of cancers (LUSC, TGCT, THYM, HNSC, BRCA, SKCM, STES, GBMLGG, GBM, PAAD, ALL, and ESCA), but positively correlated with CD8+ T cells in 5 types of cancers (KIPAN, LIHC, LAML, PCPG, and CHOL) (Figure 13B)." should be changed to "SLC2A1 expression is negatively correlated with CD8+ T cells in 11 types of cancers (LUSC, TGCT, THYM, HNSC, BRCA, SKCM, STES, GBMLGG, GBM, PAAD, and ESCA), but positively with CD8+ T cells in 5 types of cancers (KIPAN, LIHC, LAML, PCPG, and CHOL) (Figure 13B)."

The gene symbols of Figure 10 were not correct. The corrected Figure 10 appears below.



Citation: Zheng, H.; Long, G.; Zheng, Y.; Yang, X.; Cai, W.; He, S.; Qin, X.; Liao, H. Correction: Zheng et al. Glycolysis-Related SLC2A1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy.

Cancers 2022, 14, 5344. Cancers 2023, 15, 586. https://doi.org/10.3390/cancers15030586

Received: 7 December 2022 Accepted: 10 January 2023 Published: 18 January 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Cancers 2023, 15, 586 2 of 2




Figure 10. Relationship between SLC2A1 expression and RNA m6A-methylation-related genes in pan-cancer (*, p < 0.05).

The authors emphasize that the mistakes were entirely due to human error and oversight. The corrections do not affect the main scientific results and the final conclusions of this manuscript. The authors would like to apologize for any inconvenience caused. The original article has been updated.

Reference

1. Zheng, H.; Long, G.; Zheng, Y.; Yang, X.; Cai, W.; He, S.; Qin, X.; Liao, H. Glycolysis-Related SLC2A1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy. *Cancers* **2022**, *14*, 5344. [CrossRef] [PubMed]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.